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Background. Effectivetherapyfor HIV-infectedindividualsremainsanunmetmedical need.Promisingclinical trials withdendritic
cell (DC)-based immunotherapy consisting of autologous DC loaded with autologous virus have been reported, however, these
approaches depend on large numbers of HIV virions to generate sufficient doses for even limited treatment regimens.
Methodology/Principal Findings. The present study describes a novel approach for RT-PCR amplification of HIV antigens.
Previously, RT-PCR amplification of autologous viral sequences has been confounded by the high mutation rate of the virus which
results in unreliable primer-template binding. To resolve this problem we developed a multiplex RT-PCR strategy that allows
reliable strain-independent amplification of highly polymorphic target antigens from any patient and requires neither viral
sequence data nor custom-designed PCR primers for each individual. We demonstrate the application of our RT-PCR process to
amplify translationally-competent RNA encoding regions of Gag, Vpr, Rev and Nef. The products amplified using this method
represent a complex mixture of autologous antigens encoded by viral quasispecies. We further demonstrate that DCs
electroporated with in vitro-transcribed HIV RNAs are capable of stimulating poly-antigen-specific CD8+ T cell responses in vitro.
Conclusion/Significance. This study describes a strategy to overcome patient to patient viral diversity enabling strain-
independent RT-PCR amplification of RNAs encoding sequence divergent quasispecies of Gag, Vpr, Rev and Nef from small
volumes of infectious plasma. The approach allows creation of a completely autologous therapy that does not require advance
knowledge of the HIV genomic sequences, does not have yield limitations and has no intact virus in the final product. The
simultaneous use of autologous viral antigens and DCs may provoke broad patient-specific immune responses that could
potentially induce effective control of viral loads in the absence of conventional antiretroviral drug therapy.
Citation: Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, et al (2008) Multiplex RT-PCR Amplification of HIV Genes to Create a
Completely Autologous DC-Based Immunotherapy for the Treatment of HIV Infection. PLoS ONE 3(1): e1489. doi:10.1371/journal.pone.0001489
INTRODUCTION
Immunotherapeutic strategies for HIV-infected individuals are
focused on eliciting antiviral CD8+ T cell responses to control the
level of HIV virus in vivo. Evidence that cellular immune responses
play an important role in controlling HIV infection is supported by
several observations including: a) Frequencies of CTL inversely
correlate with HIV plasma levels [1] b) Blocking CD8+ T cells
with anti-CD8-specific antibodies in SIV-infected macaques
correlates with loss of viral control [2], c) resolution of acute
viremia in the SIV macaque model requires circulating CD8+ T
[3], d) The presence of virus-specific CTL coincides with the
appearance of mutant viruses which are no longer recognized by
these CTL [4], and e) The presence of CD8+CD28+ T cells are
reportedly associated with long-term non-progression [5,6].
Many current HIV immunotherapies utilize individual consen-
sus antigens or defined epitopes derived from those reference HIV
sequences. Potential therapies based on clade-specific consensus
antigens have been investigated in over 80 clinical trials, however,
the results demonstrate a consistent lack of efficacy [7–9]. While
augmentation of immune responses to consensus sequences used
for immunization was demonstrated, these therapies did not result
in reduction of viral loads. Evidence suggests that the lack of HIV-
protective immunity is attributed to sequence divergence between
autologous and consensus antigens. The high HIV mutation rate
results in novel variants which encode point mutations within CTL
epitopes and escape recognition by specific T cells. Studies with
overlapping peptides confirmed that CTL recognizing autologous
peptides encoded within a known HIV virus did not cross react
with corresponding consensus sequences [10]. Studies on humans
and non-human primates correlate virus escape from CTL with
progression to AIDS [11–13]. In addition, each patient creates a
unique environment for its own viral evolution. Consequently,
there is substantial mutational variation between the virus
infecting the patient and the reference sequences upon which
most HIV immunotherapies are based. Also, since virus sequence
diversity defines HIV clades, therapies based on consensus
antigens from one clade may have limited ability to cross control
evolutionally divergent viruses from other clades. Therefore,
therapies based on autologous viral antigens would have broader
applicability since the therapy would be perfectly matched to the
virus species infecting each subject. To date, the only successful
immunotherapies for HIV-infected patients used dendritic cells
loaded with autologous viral antigens. Independent clinical studies
by Lu et al., and Garcia et.al., demonstrated for the first time that
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loaded DC therapy can lead to durable control of viral load
[14,15]. Although these clinical studies demonstrated the potential
utility of an autologous DC therapy, the choice of whole
inactivated HIV virus as an immunogen is not ideal and may
have significant safety and practical limitations.
In the present study we report on strain-independent RT-PCR
amplification of four HIV antigens to generate templates for in vitro-
transcribed RNA. Previously a major obstacle to RT-PCR
amplification of autologous viral sequences was designing functional
PCR primers due to the high mutation rate of the virus. To resolve
thisproblem,wedevelopedamultiplexRT-PCRstrategythatallows
reliable strain-independent amplification of highly polymorphic
target antigens from any patient without the requirement for first
knowing the viral sequence and custom-designing of PCR primers
for each individual. The amplified products contain a complex
mixture of autologous antigens encoded by viral quasispecies. We
furtherdemonstrate thatin vitro-transcribed RNA can be delivered to
DCs where the encoded antigens are expressed, processed, and
presented by MHC class I molecules on the cell surface.
Regions for Gag, Vpr, Rev and Nef were selected for
amplification to generate this completely autologous RNA-
transfected DC therapy which lacks infectious virus in the final
formulation, thereby circumventing potential safety concerns. The
choice of antigens targeted for amplification was based on the
several criteria: a) Substantial regions of the target gene had to be
amenable to PCR amplification using our primer design strategy,
b) Antigen expression should not adversely affect dendritic cell
function and c) Antigens had to induce functional CTLs [16–21].
The simultaneous use of autologous viral antigens and DCs may
provide for a broad patient-specific immune response that could
potentially provide better control of residual virus or rebound of
virus following the cessation of antiretroviral therapy.
RESULTS
Successful amplification of multiple HIV RNA
antigens using the devised multiplex RT-PCR
protocol
Amplification of specific HIV genome regions is complicated by
the high sequence diversity of the HIV genome. This sequence
diversity prevents the design of a single universal primer pair for
each gene of interest. To overcome this, we designed pools of
forward and reverse primers for each target gene (i.e., Gag, Rev,
Vpr and Nef) such that most virus strains will react with at least
one forward and one reverse primer. Schematic representation of
the primer design and strategy for the HIV RNA amplification are
presented in Figure 1. This strategy provides for reliable
amplification of intended target antigen genes, as well as the co-
amplification of existing HIV quasispecies. A list of individual
primers is given in Table 1 and the composition of primer groups
is given in Table 2. The number of amplification reactions for
each HIV antigen was as follows: 6 for Gag, 4 for Vpr, 3 for Rev,
and 2 for Nef. We amplified the four antigens from archived
frozen plasma infected with diverse clades of HIV: B, C and AG
(Figure 2, panels A–C). 2–3 mL of plasma were used to isolate
HIV RNA and the titers of these three samples were of 53,334,
53,703 and 154,882 copies/mL, respectively. 2.5 mL of each
eluted RNA was used in an RT-PCR for each antigen
irrespectively of the initial viral load. PCR resulted in a productive
amplification of DNA fragments of expected size for each antigen
from all three samples.
The example of purified products from preparative PCR is
shown in Figure 2, Panel D. The reactions were set exactly as
the secondary PCR reaction described in the Methods, but in
identical replicates to generate sufficient mass of cDNA for the in
vitro transcription reaction. Sequence analysis of these fragments
confirmed that the amplified cDNAs correspond to Gag, Vpr, Rev
and Nef. Products from the nested PCR reactions were transcribed
in vitro to generate RNA and all four antigens were transcribed
successfully (Figure 2, Panel E).
Because of the HIV genome diversity and presence of deletion
and insertions within the open reading frames of interest, the
molecular weight of cDNA is expected to vary. We performed a
detailed analysis of cDNA and in vitro-transcribed RNA molecular
weights for all four antigens amplified from 10 distinct infectious
plasma samples. The size of the cDNA was measured by migration
on an agarose gel relative to molecular weight markers. The
observed size distribution of the cDNA analyzed by non-
denaturing agarose gel electrophoresis was 15726150 for Gag,
293625 for Vpr; 496625 and 841650 for Nef. The observed size
distribution for amplified RNA analyzed by denaturing agarose gel
electrophoresis was 1761654 for Gag, 338637 for Vpr, 427631
for Rev and 801652 for Nef. The range of molecular weights for
each antigen observed with these 10 samples is indicative of the
high degree of subject-to-subject antigen sequence diversity.
Summary of samples from 33 patients with diverse viral load from
which all four antigens were amplified is given on Table 3.
Whenever possible, a greater volume of viral plasma was used for
HIV RNA extraction to achieve higher yields of viral RNA. The
sample with the lowest viral load examined was sample 1. For this
sample the first cDNA synthesis reaction contained 2220 HIV RNA
copies. Due to the multiplex design of the amplification, the RT
reaction is divided into multiple PCR reactions. Since the Gag single
strand cDNA is divided between 6 PCR reactions, the actual copy
number in each PCR reaction is 370. A similar result was obtained
for sample 3 with a higher viral load but smaller volume of available
plasma. For this sample, each RT reaction contained 1580 copies of
RNA and each PCR reaction for Gag contained 263 copies of
cDNA. The calculation of final recovered HIV RNA concentration
assumes no loss during the extraction procedure. With losses, the
absolute copy requirement would be even lower. Overall these data
demonstrate consistently successful amplification of all four antigens
from plasma samples with diverse viral loads.
Multiplex PCR method amplifies diverse HIV
quasispecies
An advantage of this approach for antigen generation is its ability
to capture HIV mutations which evolve under dynamic host CTL
pressure [11]. It is broadly applicable to the general HIV-infected
population irrespective of Clade designation, but also anticipates
that it would capture various quasispecies present in a given
subject. This is the cornerstone of our novel therapeutic paradigm
which enables targeting, not only of dominant viruses, but also
newly emerging virus populations which evolve as a result of
immune pressure.
To test our hypothesis that multiple quasispecies are co-
amplified from a given subject, PCR fragments encoding full
length Nef cDNA amplified from Clade B samples HTM-349,
HTM-367 and HTM-344 (viral load 513,000; 53,334 and 95,637
copies per mL respectively) were cloned, sequenced and analyzed
using phylogenetic tree analysis. A total of 15 clones were analyzed
for each subject (Figure 3). The analysis demonstrated that the
cDNA population did indeed capture genes encoded by various
HIV quasispecies. Phylogeneic tree analysis demonstrated that
each subject’s Nef sequences grouped within other sequences from
that subject and were distinct from another subjects’ sequences.
RT-PCR for Autol DC Therapy
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the Nef variable sequences differed in each subject. At the
nucleotide level (Figure 3, Panel A) the subject HTM 344
displayed greater diversity where out of 15 clones analyzed, 14
clones were unique, followed by subject HTM 367 with 13 unique
clones and for subject HTM 349 only 6 unique clones. The
subject-specific sequence clustering together with the variable
number of unique clones between patients eliminates the
possibility that the mutations are random mutational artifacts
introduced during RT-PCR. Not every nucleotide mutation leads
to an amino acid substitution, so the diversity is lower at the level
of amino acid sequence (Figure 3, Panel B) with the same order
of diversity trend for the three subjects. Similar analyses were
performed for cDNAs encoding Gag, Rev and Vpr cDNA
amplified from various subjects (data not shown). These data
indicate that, as predicted, the multiplex RT-PCR is capable of
capturing various quasispecies within each individual subject.
We next performed further analysis of the Nef sequences and
scored individual primers on the level of productive secondary
PCR reactions. Since the same formulation of primers was used
with all samples independent of clade, we were interested to learn
which primers within the formulated groups were leading to
productive amplification and analysis of preferential use of forward
and reverse primers was performed (Table 4). The forward
primer utilization of sample HTM 344 demonstrated that 12 out
of 15 clones were formed by primer F8343.1, however in sample
HTM 367 a different primer, F8343 formed the majority of
clones. Interestingly, a novel primer annealing sequence was
identified. The sequence was termed ‘‘new’’ and differed from
either F 8343 or F8343.1 primer sequence by 2 nucleotides in the
most 39 position. We believe that the new sequence was formed
due to the 39 exonuclease proof-reading activity of the PCR
enzyme. Similarly, different preferences for use of reverse primers
were observed although no new reverse primers were identified in
all three groups analyzed. The 39 end of the PCR fragment is
defined by the cDNA synthesis step during the RT reaction, and
the lack of ‘‘repaired’’ primers is most likely due to lack of
proofreading activity in the RT enzyme. Similar analyses were
performed on multiple Rev clones and confirmed the original
observation (data not shown). Since the sequence within regions of
interest varies from patient to patient, the preferred utilization of
the primers in the PCR reactions differ as well.
Figure 1. Amplification of autologous HIV sequences using multiplex PCR. Panel A. Sequence alignment of multiple HIV isolates, revealed a region
of relative conservation with variable residues in positions 7847 and 7848. Primer REVF7830 is perfectly complimentary to consensus sequence B,
whereas primers REVF7830.1 and REVF7830.2 encode compensatory mutations in the 39 region of the primer, indicated in bold. ???denotes deletions,
-sequence identity, letters indicate alternative bases in the corresponding positions relative to consensus sequence B. Consensus sequences for
common HIV clades as well as less frequent isolates are denoted in bold. Panel B. Schematic overview of the Rev RNA amplification strategy. Open
bar denotes regions outside of open reading frame of interest, hatched bar denotes RNA region exon 2 Rev, grey bar represent DNA intermediate
products durig amplification process. For details on primer design and amplification refer to Method section.
doi:10.1371/journal.pone.0001489.g001
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T cells in vitro
The goal of active HIV immunotherapy is to stimulate the
preferential expansion of antiviral effector T cells. To demonstrate
that HIV RNAs generated by our approach can express antigens
capable of inducing CD8+ T-cell immunity, we prepared DC
electroporated with all four autologous HIV antigens encoded as
RNAs. 1 mg Gag RNA, 0.25 mgN e fR N A ,1mg Rev RNA, and
1 mg Vpr RNA were electroporated along with 1 mgo fC D 4 0 L
RNA per 10
6 DC. Since cells were fully matured by overnight
incubation inthepresenceof TNFa,I N F c and PGE2 the maturation
statusoftheDCsdidnotchangeafterelectroporationwiththeRNAs
(Data not shown). These cells were co-cultured with autologous
PBMCs pre-labeled with CFSE. After 6 days of co-culture, the
frequency and phenotype of proliferating cells was detected by
residual CFSE fluorescence within the CD8+ T cell population with
effector (CD45RA+/CD282) or effector/memory (CD45RA2/
CD28+) phenotypes. After 6 days of co-culture, the CD8+ T-cell
population was stimulated with either eGFP RNA-transfected DC
(negative control) or HIV RNA-transfected DC. The frequency of
CFSE-low cells stimulated with GFP RNA-loaded DC was 3.75%
while those stimulated with HIV RNA-loaded DC had a frequency
of 7.41% (Figure 4 Panel A). No proliferation above the negative
control background was observed within the CD4+ T cell subset,
with all DC populations inducing ,1% CD4+ CFSE-low cells
within total PBMCs (data not shown). Within the proliferating
CFSE-low CD8+ T cell subset stimulated with HIV RNA-loaded
DC, 24.7% of cells exhibited a phenotype consistent with fully
differentiated effector cells (CD8+CD282CD45RA+)v e r s u s5 4 . 8 %
of cells had a phenotype indicative of effector/memory cells
(CD8+CD28+CD45RA2)( Figure 4 Panel B).
To assess the specificity and effector function of the T cells
responding with antigen-induced proliferation, the cultures were
further re-stimulated with either DC electroporated with GFP
RNA (negative control), a pool of all 4 HIV RNAs, or each HIV
RNA independently. After 4 hours CFSE-low CD8+ T cells were
tested for IFN-c expression by intracellular staining. Induction of
IFN-c expression above the GFP negative control background was
observed for all HIV RNA DC-stimulated cultures (Figure 4,
Panel C). Co-cultures that were originally established with GFP
RNA-electroporated control DC for 6 days and then restimulated
Table 1. List of primers designed for amplification of HIV Gag,
Rev, Vpr and Nef regions.
......................................................................
Primer Name Primer Sequence
GAG F 124 ACTCTGGTAACTAGAGATCC
GAG F 304 AATTTTGACTAGCGGAGGC
GAG F 334 AGATGGGTGCGAGAGCGT
GAG F 334.1 AGATGGGTGCGAGACCGT
GAG R 1881 GCTCCTGTATCTAATAGAGC
GAG R 1881.1 GCTCCTGTATCTAATAAAGC
GAG R 1881.2 GCTCCTGTATCTAACAGAGC
GAG R 1913 TTTGGTTTCCATCTTCCTGG
GAG R 1913.1 TTTGGTTTCCATCTTCCTGC
GAG R 1913.2 TTTGGCTTCCATCTCCCTGG
GAG R 1913.4 TTTGGTTTCCATTTCCCTGG
GAG R 1913.5 TTTGGTTTCCATTTTCCTGG
VPR F 4995 GCAGGACATAACAAGGTAGG
VPR F 4995.4 GCAGGACATAACAAAGTAGA
VPR F 5058 AAGATAAAGCCACCTTTGCC
VPR R 5507 TTCTTCCTGCCATAGGAGATGC
VPR R 5507.1 TTCTTCCTGCCATAGGAAATGC
VPR R 5419 GCAGTTGTAGGCTGACTTCC
VPR R 5419.1 GCAGTTGTAGGCTGACTCCC
VPR R 5419.2 GCAGTTGTAGGCTGGCTTCC
REV F 7750 GGGATTTGGGGTTGCTCTGG
REV F 7750.1 GGGATTTGGGGCTGCTCTGG
REV F 7830 TGATAGTAGGAGGCTTGGTAGG
REV F 7830.1 TGATAGTAGGAGGCTTAATAGG
REV F 7830.2 TGATAGTAGGAGGCTTGATAGG
REV F 7911 GTTAGGCAGGGATATTCACC
REV F 7911.1 GTTAGGCAGGGATACTCACC
REV R 8300 CCCTGTCTTATTCTTCTAGG
REV R 8300.1 CCCTGTCTTATTCTTACAGG
REV R 8300.2 CCCTGTCTTATTCTTGTAGG
NEF F 8235 TAGCTGAGGGGACAGATAG
NEF F 8235.1 TAGCTGAGGGAACAGATAG
NEF F 8235.2 TAGCTGGCTGGACAGATAG
NEF F 8343 ATGGGTGGCAAGTGGTCAAAAAG
NEF F 8343.1 ATGGGTGGCAAGTGGTCAAAACG
NEF F 8343.2 ATGGGTGGCAAATGGTCAAAAAG
NEF F 8343.3 ATGGGTGGCAAGTGGTCAAAAGG
NEF R 9069 CCAGTACAGGCAAAAAGC
NEF R 9069.1 CAGTACAGGCGAAAAGC
NEF R 9069.2 CAGTACAGGCAAGAAGC
All sequences listed in 59-39 orientation. 59 primers are represented by letter F
(forward) and 39 primers are represented by letter R (reverse). Numbers
correspond to relative location of each primer within sequence chosen as the
reference.
doi:10.1371/journal.pone.0001489.t001
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Table 2. Composition of primer groups.
......................................................................
GAG F 124 VPR F 4995 REV F 7750 NEF F 8235
GAG F 124 VPR F 4995 REV F 7750 NEF F 8235
GAG F 304 VPR F 4995.4 REV F 7750.1 NEF F 8235.1
GAG F 304 VPR F 5058 REV F 7830 NEF F 8235.2
GAG F 334 VPR F 5058 REV F 7830 NEF F 8343
GAG F 334 VPR R 5507 REV F 7830.1 NEF F 8343
GAG F 334.1 VPR R 5507 REV F 7830.2 NEF F 8343.1
GAG R 1881 VPR R 5507.1 REV F 7911 NEF F 8343.2
GAG R 1881 VPR R 5419 REV F 7911 NEF F 8343.3
GAG R 1881.1 VPR R 5419 REV F 7911.1 NEF R 9069
GAG R 1881.2 VPR R 5419.1 REV R 8300 NEF R 9069
GAG R 1913 VPR R 5419.2 REV R 8300 NEF R 9069.1
GAG R 1913 REV R 8300.1 NEF R 9069.2
GAG R 1913.1 REV R 8300.2
GAG R 1913.2
GAG R 1913.4
GAG R 1913.5
Primers were combined according to their position in the genome.
Bold indicates the primer group name. Non-bold: names of the primers which
comprise each primer groups. Sequence of all primers is given in Table 1.
doi:10.1371/journal.pone.0001489.t002
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PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1489with individual HIV antigen-encoding RNA-electroporated DC
all expressed less than 0.15% IFN-c activity within the CD8+
CFSE-low subset (data not shown).
DISCUSSION
The strategy of the HIV therapy using autologous DC loaded with
autologous antigen has been successfully tested in two clinical trials
[14,15]. The HIV therapy described here exploits similar
therapeutic principles of the autologous approach but with added
advantages in terms of potential safety and applicability to a
broader HIV-infected patient population.
Our approach requires only a small amount of patient plasma,
which may be pivotal for eventual commercial-scale manufactur-
ing. We demonstrated amplification from samples containing as
little as 263 or 370 copies of cDNA in a single PCR reaction.
Many RT-PCR methods such as HIV sequence detection methods
detect as low as 50 copies or even a single copy [22–24]. However,
such methods developed for high sensitivity detect only small
amplicons and do not require an intact HIV genome. To clone
longer HIV fragments, 1,000 copies of the HIV genome are
required for use in the initial RT reaction [25]. Therefore, the
HIV RNA copy requirements described here is comparable to
those reported in the literature. Due to the fact that RNA is
amplified, first through RT-PCR, and then by in vitro transcription,
milligram-scale RNA masses can be achieved, sufficient to
transfect large numbers of autologous DCs.
The complete coding regions for p55 Gag and Nef and partial
products for Rev and Vpr were amplified. The full length Rev
mRNA is formed in the course of a trans-splicing reaction which is
not possible to reproduce in vitro. Since the exon 1 of Rev encodes
only 25 amino acids we designed primers to amplify exon 2 only.
The ATG initiation codon which enables translation of that RNA
is introduced in the context of a secondary PCR primer. In the
case of Vpr, primers were designed to amplify the sequence coding
for amino acids 1–71 only. All of the predicted epitopes for CTL
recognition within the Vpr protein are located between amino
acids 12–70 (http://www.hiv.lanl.gov/content/immunology). The
approach of expressing functionally inactive HIV genes which are
still able to successfully induce immunity have been documented
by others [26].
Our ability to amplify HIV sequences in a clade-independent
manner rests on the principles of multiplex RT-PCR technology.
Figure 2. Successful clade-independent amplification of HIV RNA encoding for antigens from infectious plasma. Panel A: Agarose gel
electrophoresis analysis of PCR fragment obtained from three diverse plasma. Amplification from subject plasma infected with Clade B sample. M:
100 bp DNA ladder (Invitrogen). Panel B: Amplification from subject plasma infected with Clade C virus. M: 100 bp DNA ladder (Invitrogen). Panel C:
Amplification from subject plasma infected with Clade AG virus. M: AmpliSize DNA ladder (BioRad). Analysis of products obtained after the secondary
PCR reaction for Gag, Vpr, Rev, and Nef as marked on the top. Panel D. cDNA obtained in preparative secondary PCR reaction corresponding to Gag,
Vpr, Rev, and Nef antigens. M: 100 bp DNA ladder (Invitrogen). The molecular weight of representative DNA bands is indicated on the left. Panel E.
RNA corresponding to Gag, Vpr, Rev, and Nef antigens obtained by in vitro transcription using amplified PCR products from subjects plasma. M:
molecular weight RNA ladder (Promega), representative marker sizes are indicated on the left. G, V, R, N: in vitro transcribed RNAs for Gag, Vpr, Nef
and Nef respectively.
doi:10.1371/journal.pone.0001489.g002
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PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1489First, different loci within HIV genomes are targeted in primary
PCR reactions and secondly, each primer group is composed of
primers which are complementary to target sequences as well as
additional primers carrying compensatory mutations. During the
annealing step the most complementary primer-template combina-
tion givesrisetoa primary productwhich isthenamplified furtherin
a secondary PCR reaction. We believe that because the template is
first amplified in a course of primary PCR, mismatches between
primary PCR fragments and secondary PCR primers is more
forgiving and allows for productive amplification. Therefore greater
numbers and combinations are required for the primary PCR
reactions. This study demonstrates the feasibility of target region
amplification from infectious plasma encompassing various HIV
virus clades as well as diverse viral loads. We also demonstrate that
this process captures various quasispecies within a single patient. We
also observed that the diversity of Nef sequences found in subject
HTM-349 is dramatically reduced compared to the other two
subjects analyzed. It would be interesting to determine whether the
low diversity of Nef sequences is due to a lack of Nef-specific CTLs
within that patient consistent with the hypothesis that immune
pressure drives the evolution of Nef variants. We believe that the
ability to capture autologous sequences of HIV virus and all
quasispecies arising as a result of the CTL pressure is the foundation
for the successful anti HIV immunotherapy.
While translated protein from the RNAs encoding the four
individual antigens was studied in the DC, we were unable to devise
a universal method of detection or identify an antibody which could
cross-react with all subject-specific amplified material. Also, the
sensitivity of these methods isinsufficient to detectprotein expression
whenarelativelylowamountofRNA(1 mgorless)isdeliveredtothe
DCs. Instead we elected to study presentation of antigens by RNA-
electroporated DC with detection of induced T-cell responses as a
surrogate assay for protein expression using PBMCs derived from a
successfully HAART-treated HIV-infected donor. Autologous RNA
rather than consensus-sequence- based reagents (vectors, peptides,
etc.) was used to transfect DCs to maximize the probability of
antigen recognition
Flow cytometric analysis of T cell- DC co-cultures demonstrated
that DCs electroporated with the four HIV antigen-encoding
RNAs successfully induced specific proliferation and effector
function (IFN-c activity) to all four antigens within the responder
CD8+ T cell subset in this experiment. Both qualitative and
quantitative issues contribute to the reported immune responses.
The RNAs used in this experiment have different molecular
weights: 1.5 kb for Gag and 0.3 kb for Vpr thus the number of
molecules of each RNA is inversely proportional to the mass used.
Under the conditions used in the experiment shown in Figure 4,
the relative number of molecules delivered to the DC is greater for
Vpr and lower for Gag. Figure 4C shows the correlation of antigen
reactivities (as measured by IFN-c release) supporting the idea that
for this donor, the relative epitope densities presented on the
surface of the DC is proportional to the number of RNA
transcripts electroporated for each antigen.
The preferential targeting of Vpr with CTLs was also reported
by others [20]. However, it is well documented that different
patients can have qualitatively different preferential epitopes
reactivities resulting in non-linear relationships with antigen
expression levels or epitopes densities on antigen presenting cells.
This relationship is further impacted by differences in TCR avidity
for specific epitopes or proteosome processing preferences which
can vary from patient to patient and whether the predominant
infecting virus species encode mutated epitopes [27]. A study of
monozygotic twins infected at the same time with the same virus
demonstrated that while some CD8 T cell specific responses were
the same, some discordinant T cell responses were also found [28].
The discordinant responses cannot be simply explained by virus
phenotype or HLA epitope restriction and suggests that additional
factors play a role in selection of epitope recognition.
We also noted that the majority of the cells responding to HIV
antigens with proliferation and IFN-c production exhibited a
CD28+/CD45RA- ‘effector/memory’ phenotype which has been
linked to long-term non-progression [5,6]. Collectively, these data
provide strong evidence that, at least in vitro, HIV antigens encoded
by RNA can be translated and presented by DC to induce poly-
antigenimmunity.Suchactivityispresumed tobeanessential aspect
of an immunotherapeutic designed to control HIV viral escape. In
addition, no specific activity was recorded within the CD4
+ subset,
consistentwith theinabilityofantigenencoded by RNA toefficiently
Table 3. List of samples tested for HIV RNA amplification.
......................................................................
sample
number
viral load
RNA/mL
volume of
plasma used clade
coies of RNA
per RT reaction
1 7,413 3 B 2220
2 14,791 3 B 2220
3 15,849 2 C 1580
4 16,596 3 B 2480
5 18,197 3 B 5460
6 22,155 3 B 3320
7 22,909 2 AG 2300
8 28,840 3 B 8640
9 33,884 3 B 10160
10 38,663 3 B 5800
11 38,905 3 B 5840
12 45,709 3 B 6860
13 48,627 1 Nd 2440
14 50,070 1 Nd 2500
15 50,119 3 B 7520
16 50,119 3 B 7520
17 53,334 2 B 5340
18 53,703 2 C 5360
19 53,725 3 B 8060
20 72,865 1 Nd 3640
21 72,978 1 nd 3640
22 95,637 2 B 9560
23 117,490 3 B 17620
24 131,826 3 B 19780
25 134,000 3 B 20100
26 146,148 1 B 7300
27 154,882 3 AG 23240
28 158,489 3 B 23780
29 244,000 1 B 12200
30 513,000 3 Nd 38480
31 1,138,560 3 B 170780
32 1,479,108 3 Nd 221860
33 3,221,835 1 B 161100
Samples acquired as indicated in various geographical locations; nd: data not
available; viral load test was estimated by approved clinical laboratory methods
(Amplicor HIV assay Roche or bDNA Bayer); copies of RNA per RT reaction
calculated assuming no loss of HIV RNA during isolation procedure. All samples
obtained from randomly selected patients.
doi:10.1371/journal.pone.0001489.t003
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1489target the endosomal pathway [29]. We speculate that there may be
specific advantages to being able to induce antiviral CD8+ Tc e l l
immunity without concomitant expansion of CD4+ T cells which
might serve as a reservoir for virus and facilitate enhanced viremia.
The breadth of the CTL repertoire has been shown to correlate
with anti-HIV-protective immunity. In an animal model compar-
ing immune responses in groups of animals immunized with either
a gag-pol-encoding DNA vector, codon optimized Gag-Pol, or
multivalent Expression Library Immunization (ELI) therapeutics,
the induced immune responses were up to 10-fold higher in the
group immunized with the multivalent (ELI) therapeutic than the
other two constructs tested [30]. Also, improved protection against
simian AIDS was reported in a study with an experimental
immunotherapy directed against six antigens (Gag, Pol, Env, Rev,
Tat, Nef) compared to one directed against only three antigens
(Gag, Pol, and Env) [21]. In addition, immunotherapies targeting
multiple regions of the viral genome have the potential to force the
accumulation of multiple mutations as a consequence of polyvalent
CTL pressure which can drive the virus into a state of poor
replicative fitness [31].
This study establishes the feasibility of multiplex RT-PCR-
mediated amplification of autologous RNA encoding HIV antigens
from small volumes of infectious plasma. We also demonstrate that
this approach captures multiple quasispecies present within a given
subject which could allow the induction of multivalent CTL
responses, a critical factor in minimizing the chances of rapid
emergence of viral escape variants. Furthermore, we demonstrate
ability of DCs transfected with autologous amplified HIV antigen
RNA to induce antigen-specific CD8+ Tc e l l s .
METHODS
Design of primers for strain-independent
amplification of HIV antigens
The strategy used to design primer pools for PCR amplification for
the selected HIV antigens, using the Rev sequence as an example,
is summarized in Figure 1, Sequences of HIV isolates were
aligned using BLAST analysis with sequence NC_001802 serving
as an arbitrary reference [32,33]. Nucleotide regions which
appeared to have sequence conservation were selected for primer
Figure 3. Capture of HIV quasispesies using the developed multiplex RT-PCR approach. Phylogenetic relationships of nucleotide sequences of
isolated full-length Nef clones (Panel A) and amino acid sequences (Panel B). Horizontal scale indicates the number of nucleotide mutations or amino
acid substitutions on each clone relative to neighbor clones.
doi:10.1371/journal.pone.0001489.g003
Table 4. Selective utilization of primers by RT-PCR from various subjects materials.
..................................................................................................................................................
Utilization in RT-PCR in various subjects
Primer name Primer sequence 59-39 HTM 344 HTM 349 HTM 367
T7 Nef F 8343 TAATACGACTCACTATAGGGAGACCACCATGGGTGGCAAGTGGTCAAAAAG 101 0
T7 Nef F 8343.1 TAATACGACTCACTATAGGGAGACCACCATGGGTGGCAAGTGGTCAAAACG 12 0 0
New TAATACGACTCACTATAGGGAGACCACCATGGGTGGCAAGTGGTCAAAAGG 21 5 5
TAATACGACTCACTATAGGGAGACCACCATGGGTGGCAAGTGGTCAAAAAT
64T Nef R 9069 (T)64CCAGTACAGGCAAAAAGC 7 8 11
64T Nef R9069.1 (T) 64CAGTACAGGCGAAAAGC 6 2 4
64T Nef R9069.1 (T) 64CCAGTACAGGCAAGAAGC 2 5 0
The Nef cDNA sequences were analyzed in the regions corresponding to the regions defined by the primers and identity of the primers was identifies by sequence.
Total of 15 Nef clones were analyzed for subjects HTM344, HTM 349 and HTM 367. The number in the right three columns represents how many clones contained the
identified primer.
doi:10.1371/journal.pone.0001489.t004
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PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1489design. The strategy used to design primers for PCR amplification,
using Rev sequence as an example, is summarized in Figure 1.A s
shown a primer that is complimentary to the consensus B sequence
was designed (Rev F 7830). Alternative primers which could also
accommodate the frequently found mutations in this location were
designed as well. These alternative primers contain compensatory
sequence variations to accommodate the frequently found
mutations in positions 7847 and 7848 (Rev F 7830.1 and Rev F
7830.2).
To minimize the number of primers used, a mismatch at the 59
end of a primer sequence was tolerated since lowering the PCR
amplification stringency could compensate for such mismatches.
However, mismatches at the 39 end of a primer sequence were
avoided
To enable transcription of the PCR product in vitro, the products
of the primary PCR reaction were modified to insert a T7 RNA
polymerase binding site at the 59 end (Figure 1). Naturally
occurring translation initiation codons for Gag, Vpr and Nef were
captured during PCR amplification. However Rev mRNA is
formed in a transplicing event and capture of a full length cDNA
via PCR is not achievable. Only the second exon of Rev is
amplified, so the addition of the initiator ATG codon for the Rev
antigen in a nested round of PCR is required in order to enable
translation initiation. The reverse primers contain a poly(T)64 tail
which is transcribed into a poly(A)64 tail on the synthesized RNAs.
(Figure 1). Individual primer sequences for the primary round of
amplification are provided in Table 1.
Formulation of primer groups
Oligonucleotides (IDT) were reconstituted at a concentration of
100 mM. Primers were combined into groups to reduce the
number of PCR reactions (the composition of primer groups is
provided in Table 2. The final primer concentration in
formulated stock solutions was 5 mM for PCR, and 20 mM for
gene-specific reverse transcription. The amplification protocol was
simplified by grouping primers according to their location. The
number of amplification reactions for each HIV antigen was
significantly reduced from the scenario where individual primer
combinations would be used: 6 for Gag, 4 for Vpr, 3 for Rev, and
2 for Nef. Once primer mixes were made they were not further
changed and the same formulations of primers were used to
amplify various plasma materials.
Figure 4. Panel A: CFSE-low cells expressed as a percentage of total PBMCs. Mature DCs (CD209: 96%; CD14: 0%; CD80: 100%; CD83: 91%; CD86:
100%; HLA-DR: 96%; and HLA-I: 100%) were electroporated with 4 HIV antigen-encoding RNAs (hatched bar) or eGFP (solid bar) were cultured with
CFSE-labeled PBMCs for 6 days. Frequency of CD8+ CFSE-low were cells determined by flow cytometry. Panel B: CD28/CD45RA phenotype of CD8+
cells induced to proliferate (CFSE-low) by DC electroporated with 4 HIV antigen-encoding RNAs (left panel), as compared to the frequency of CD8+
CFSE-low cells induced by eGFP-RNA loaded control DC (right panel), as determined by flow cytometry. Panel C: Frequency of IFN-c positive cells
within the CD8+ CFSE-low subset induced by 4 hr re-stimulation with DC expressing individual HIV antigen-encoding RNAs, or eGFP control RNA, as
determined by intracellular staining and flow cytometry. The background response for single HIV RNA stimulators (1ug HIV RNA/10
6 DC) was
calculated at 0.38% from GFP RNA-electroporated DC (1ug GFP RNA/10
6 DC) and is indicated by the horizontal dashed line.
doi:10.1371/journal.pone.0001489.g004
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patient plasma
HIV RNA was isolated from 1 to 3 mL of plasma from HIV
patients using a NucliSens kit (BioMerieux), according to the
manufacturer’s instructions and eluted in 30 mL of nuclease free
water. First strand cDNA synthesis reaction contained gene-
specific primers for either Gag, Vpr or Rev, and oligo dT(20)
(Invitrogen) for Nef, 40 units of RNAseOut (Invitrogen), 0.5 mM
of each dNTP (Clontech), and Superscript first strand buffer. After
annealing at 65uC for 5 minutes, DTT to 5 mM and 400 units of
Superscript III (Invitrogen) were added and the reaction was
incubated at 55uC for 1 hour.
2.5 mL of the first strand cDNA reaction was then taken into a
primary PCR reaction containing 5 units of PFU ultra HS, PFU
buffer (Stratagene), 0.2 mM of each dNTP (Stratagene), and the
corresponding group of primers at a final concentration 0.4 mM
for Gag, 0.6 mM for Vpr, 0.2 mM for Rev, and 0.4 mM for Nef, in
a final reaction volume of 50 mL. The PCR reaction was
denatured at 95uC for 2 minutes and then run for 40 cycles as
follows: 95uC for 30 seconds, 54uC for 30 seconds, and 72uC for
3 minutes and 10 minutes for the last cycle. The annealing
temperature was kept at 54uC here and in the secondary PCR
amplification to allow for annealing of primers to templates with a
limited degree of mismatch [34]
1 mL of the primary PCR reaction was then taken into a
secondary PCR reaction containing 2.5 units of PFU Ultra HS,
PFU buffer (Stratagene), 0.2 mM of each dNTP (Stratagene), and
gene specific T7 and 64T groups of primers, in a final reaction
volume of 25 mL. The cycling parameters were the same as in the
primary PCR reaction. Products of the secondary PCR reaction
were purified using a QIAquick purification column (QIAGEN).
For preparative PCR several (i.e. 6 or 12) reactions were
established with same conditions as secondary PCR except the
total volume of each reaction was 50 mL.
PCR Amplification of HIV sequences from
noninfectious templates
Gag, Rev and Vpr were amplified from plasmid pBKBH10S and
Nef was amplified from plasmid p93TH253.3 obtained from NIH
AIDS Research & Reference Reagent program [35,36]. Single
forward and reverse PCR primers were selected with full
complementarity to the template determined by sequence analysis.
All PCR conditions were exactly the same as used for
amplification of the infectious material.
In vitro transcription of HIV antigens
Secondary PCR fragments served as templates for an in vitro
transcription reaction using mMessage mMachine T7 Ultra kit
(Ambion) according to the manufacturer’s instructions. The
amplified RNA was purified using RNeasy columns (QIAGEN).
Sequence analysis and phylogeneic relationship
Sequencing analyses were performed using the UNC sequencing
facility (University of North Carolina, Chapel Hill). Nucleotide
sequence analysis, identity verification and phylogeneic tree
analysis were performed using Lasergene software (DNAStar),
the Los Alamos HIV Sequence Database (http://www.hiv.lanl.
gov), and BLAST analysis [32,33].
Isolation of human dendritic cells
A leukapheresis sample from a volunteer was collected on a COBE
Spectra (Gambro BCT) using the AutoPBSC procedure described
by Lifeblood (Memphis, TN). Peripheral blood mononuclear cells
were isolated using a Ficoll density gradient (HistopaqueH-1007
Hybri-MaxH, Sigma) and cultured for 1 to 2 hours to allow
adherence of the monocytes. Non-adherent cells were removed
and the remaining monocytes were cultured in X-VIVO 15
TM
(Cambrex) medium for 6 to 7 days, supplemented with 1000 U/mL
eachof GM-CSF(Berlex,LeukineH liquid)and IL-4 (R&D Systems).
Generation of DC for functional testing of HIV IVT
RNAs for the induction of anti-HIV immunity in vitro
Immature DCs were generated as described above from a
successfully HAART-treated HIV donor with a viral plasma copy
number of less than 200 copies per mL. To achieve DC
maturation, immature DC were cultured on day 5 with 10 ng/
ml TNF-a, 1000 mg/ml IFN-c,1 mg/ml PGE2. On Day 6,
matured DCs were co-electroporated with in vitro transcribed RNA
encoding CD40L at 1 mg per million of DC, and 1 mg Gag, Rev,
Vpr and 0.25 mg Nef autologous HIV RNAs per million of DCs. A
negative control DC stimulator was generated by transfecting DC
with CD40L RNA and 3.25 mg eGFP RNA, instead of HIV RNA
mix. RNA-electroporated DC were further cultured for 4 hrs in
X-VIVO-15 medium without additional cytokine supplements.
In vitro co-culture of DC and PBMC from an HIV-
infected subject to induce anti-HIV T-cell responses
to multiple HIV antigens
CFSE labeling PBMCs from the HIV donor were enriched by
Ficoll gradient separation, washed twice with PBS and re-
suspended at 2.0610
7 cells per mL in PBS. CFSE was added to
the cell suspension for a final working concentration of 1.0 mM
and incubation for 8 minutes at room temperature. The staining
was quenched by the addition of an equal volume of Human AB
Serum and incubation for 2 minutes.
Initial DC/PBMC co-culture Cultures of HIV RNA-
electroporated mature DC, and eGFP-RNA control DC were
established in parallel with CFSE-labeled PBMC at a 1:10 ratio, 1
million total cells/mL in 5% Human AB serum for 6 days at 37uC,
5% CO2.
Cell surface phenotyping of proliferating CFSE ‘low’
labeled cells After 6 days of culture, PBMCs were harvested,
washed once with 2 mL PBS containing 10% FBS and stained for
surface antigens using CD45RA PE, CD8 PerCP-Cy5.5, CD28
APC or CD45RA PE, CD4 PerCP-Cy5.5, CD28 APC antibodies
(BD Bioscience) at room temperature in the dark for 20 minutes.
Samples were washed twice with cold PBS containing 10% FBS
and re-suspended in 300 mL of 2% BD Cytofix (BD Bioscience)
Samples were acquired on a BD FACSCalibur flow cytometer and
analysed using FlowJo software (Three Star, Inc.) Analysis gates
were set on the basis of FSC v. SSC to define viable lymphocytes
and lymphoblasts, and the frequency of proliferating cells
determined by detection of CFSE ‘low’ cells, and their
associated cell surface phenotype
Measurement of anti-HIV specific activity by
restimulation of PBMCs with individual DC populations
expressing a single HIV gene Immature DC were generated
as described above, matured with TNF-a, IFN-c and PGE2 and
cells split into 5 groups, allowing for DC populations to be
generated expressing just a single HIV gene from the panel of four
individual antigens, and a fifth DC population electroporated with
eGFP RNA, as negative control. The DC populations were co-
cultured in parallel with CFSE-labeled PBMC harvested from the
previous 6-day co-culture described above. One hour after re-
stimulation with DCs, 0.25 ml of Golgi plug (BD Bioscience) was
RT-PCR for Autol DC Therapy
PLoS ONE | www.plosone.org 9 January 2008 | Issue 1 | e1489added to each sample and incubated for an additional 3 hours at
37uC, 5% CO2 in RPMI containing 10% Human Serum. Samples
were washed once with 1 ml PBS containing 10% FBS and stained
for surface antigens using CD8 PerCP-Cy5.5 or CD4 PerCP-
Cy5.5 antibodies at 4uC in the dark for 20 minutes. After wash
with PBS containing 2% FBS and re-suspension in 150 mlo f2 %
BD Cytofix cells were incubated at room temperature in the dark
for 20 minutes. Samples were washed twice with 1 ml of Perm/
Wash buffer (BD Bioscience) and incubated at room temperature
in the dark for 20 minutes with 2 ml of purified Mouse IgG1
antibody. Samples were stained for intra-cellular cytokines using
IL-2 PE and IFN-c APC antibodies at room temperature in the
dark for 20 minutes. Samples were washed twice with 1 ml of BD
Perm/Wash buffer and re-suspended in 150 ml of 2% BD Cytofix,
acquired on a BD FACSCalibur flow cytometer and analyzed
using FlowJo software. PBMC that had proliferated (CFSE ‘low’)
during the previous 6-day co-culture were gated and analyzed for
induced IFN-c and IL-2 content.
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